Case Management: Glioblastoma Multiforme
Brain
Posted on: Aug 16

Case Management: Glioblastoma Multiforme

…the first antiangiogenic therapy approved for use in cancer patients…bevacizumab has demonstrated anti-tumor activity in many solid tumors, including colorectal, breast, lung, and renal cell cancers, and the results of two phase II trails show it is also effective in patients with recurrent GBM.

Stephanie A. Wagner, MD

Glioblastoma Multiforme (GBM) is an aggressive form of brain cancer that has a short clinical history, usually less than three months. GBM is a highly infiltrating tumor that cannot be totally resected. Postoperatively, the patient is treated with concurrent external beam radiotherapy and low-dose temozolomide. However, with median survival at just 12 to 15 months, a new therapy is needed. Bevacizumab is the first new drug approved for GBM in more than a decade, with six-month overall survival rates ranging from 44 to 75 percent in one clinical trial. Bevacizumab has also shown to be effective for newly diagnosed GBM, and beyond survival rates, reduces symptoms such as headache, seizure and fatigue.

Read more about bevacizumab and how it aided in the case of sustained remission in a 40-year-old male presenting with GBM.

Tags: neuroscience, brain, cancer, glioblastoma multiforme, article
What do you think of this article?

Case Management: Glioblastoma Multiforme

…the first antiangiogenic therapy approved for use in cancer patients…bevacizumab has demonstrated anti-tumor activity in many solid tumors, including colorectal, breast, lung, and renal cell cancers, and the results of two phase II trails show it is also effective in patients with recurrent GBM.

Stephanie A. Wagner, MD

Glioblastoma Multiforme (GBM) is an aggressive form of brain cancer that has a short clinical history, usually less than three months. GBM is a highly infiltrating tumor that cannot be totally resected. Postoperatively, the patient is treated with concurrent external beam radiotherapy and low-dose temozolomide. However, with median survival at just 12 to 15 months, a new therapy is needed. Bevacizumab is the first new drug approved for GBM in more than a decade, with six-month overall survival rates ranging from 44 to 75 percent in one clinical trial. Bevacizumab has also shown to be effective for newly diagnosed GBM, and beyond survival rates, reduces symptoms such as headache, seizure and fatigue.

Read more about bevacizumab and how it aided in the case of sustained remission in a 40-year-old male presenting with GBM.

What do you think of this article? print